Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16793400 | 0.81 | AAK1 (0.45) | NAMPTRAB9AMEN1NPC1KMT2A | |
| SCHEMBL1111103 | 0.80 | ADORA2A (0.47) | METAP1RAB9AATRMEN1NPC1 | |
| SCHEMBL23666719 | 0.77 | HTT (0.37) | MEN1KMT2A | |
| SCHEMBL17612599 | 0.77 | CNR2 (0.43) | RAB9AATRMEN1NPC1GAA | |
| SCHEMBL29142163 | 0.77 | ATR (0.47) | NAMPTMETAP1RAB9AATRAAK1 | |
| SCHEMBL27334225 | 0.74 | AAK1 (0.46) | ATRAAK1 | |
| SCHEMBL30770699 | 0.74 | AAK1 (0.46) | ATRAAK1 | |
| SCHEMBL1029793 | 0.74 | KDM4E (0.49) | NAMPTMETAP1RAB9AATRNPC1 | |
| SCHEMBL17654360 | 0.73 | AAK1 (0.50) | NAMPTAAK1 | |
| SCHEMBL21949678 | 0.71 | AKT1 (0.46) | NAMPTMETAP1RAB9AATRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | NAMPT 4430/4885METAP1 3908/4885RAB9A 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.